Degenerative disc disease can lead to multiple disorders, such as spondylolisthesis, retrospondylolisthesis and lumbar spinal stenosis. Approximately 90% of people witness an episode of debilitating back pain at a later point in their lives. Biopharmaceutical companies are currently targeting oral treatment and peripherally acting analgesics.
